



CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, 30 April 2024

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, article 2 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures (the “**Delegated Regulation**”) and concordant provisions, is hereby reported the following

#### OTHER RELEVANT INFORMATION

It is hereby informed that, under the authorization granted by the General Shareholders' Meeting held on May 31, 2023 for the derivative acquisition of treasury shares, Pharma Mar, S.A. (the “**Company**”) has agreed to carry out a program to buy-back treasury shares under the terms indicated below (the “**Buy-back Program**”).

The Buy-back Program will be carried out in accordance with the provisions of article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (“**Market Abuse Regulation**”) and the Delegated Regulation:

- (a) Purpose: the Buy-back Program is intended to reduce the Company's share capital by amortizing the shares acquired by virtue thereof, thus improving the earnings per share and contributing to the shareholder's remuneration.
- (b) Maximum number of shares and cash amount: the Buy-back Program will affect a maximum of 184,000 shares, representing approximately 1% of the Company's share capital on the date of this announcement, and its maximum cash amount amounts to € 5,000,000.00.
- (c) Price and volume conditions: the shares will be purchased at market price, in accordance with the price and volume conditions established in article 3 of the Delegated Regulation and, in particular:
  - (i) Maximum acquisition price: the Company will not purchase shares at a price higher than the highest of the following: (A) the price of the last independent transaction; or (B) the highest independent offer at that time in the trading venues where the purchase is made.
  - (ii) Maximum volume: the Company will not purchase on any trading day more than 25% of the average daily volume of the shares of the Company traded in the 20 business days prior to the date of each purchase in the trading center where the purchase is made.
- (d) Duration: The Buy-back Program will commence on May 6, 2024 and will remain in effect until September 30, 2024, subject to the Company being able to extend the date of its duration in view of the prevailing circumstances and in the interests of the Company and its shareholders.

Pharma Mar S.A.  
Avda. de los Reyes, 1  
P.I. La Mina  
28770 Colmenar Viejo  
(Madrid) Spain  
[www.pharmamar.com](http://www.pharmamar.com)



However, the Company may terminate the Buy-back Program if, prior to the effective date, it had acquired the maximum number of shares or the maximum cash amount authorized by the Board of Directors referred to in section (b) above or if any other circumstance that so advises occurs.

The interruption, termination or modification of the Buy-back Program, as well as the stock purchase operations carried out by virtue thereof, will be duly communicated to the National Securities Market Commission in accordance with the provisions of the Market Abuse Regulation and the Delegated Regulation.

The Buy-back Program will have JB CAPITAL MARKETS, S.V., S.A.U. as its main manager.

Likewise, to enable the start of the Buy-back Program operation, the Company has agreed to temporarily suspend, with effect from the market close on 3 May 2024, the liquidity contract entered into with JB CAPITAL MARKETS, S.V., S.A.U., which entered into force 28 June 2021, and whose operation was effective from 13 July 2021, as communicated to the market by means of a communication of Other Relevant Information of the latter date (with registration number 10,583).